2022 World Conference on Lung Cancer (ePosters)-EP05.02-012. Chemoradiotherapy versus Chemotherapy in Neoadjuvant Settings for Stage III-N2M0 Non-Small Cell Lung Cancer (NSCLC) Patients

EP05.02-012. Chemoradiotherapy versus Chemotherapy in Neoadjuvant Settings for Stage III-N2M0 Non-Small Cell Lung Cancer (NSCLC) Patients

Back to course

Pdf Summary

The purpose of this study was to compare the effectiveness of chemoradiotherapy (CRT) versus chemotherapy (CT) in the neoadjuvant treatment of stage III-N2 non-small cell lung cancer (NSCLC) patients. The study utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify adult NSCLC patients diagnosed between 2004 and 2015. The primary outcomes assessed were overall survival (OS) and cancer-specific survival (CSS). The Cox proportional hazards model was used to analyze the effect of each treatment modality on OS and CSS, adjusting for various factors such as age, sex, T stage, lymph node status, tumor histology, and surgical procedure. Inverse probability treatment weighting (IPTW) was applied to create weighted samples based on study covariates.<br /><br />The results of the study showed that the addition of radiotherapy to neoadjuvant chemotherapy did not significantly improve survival outcomes. Several prognostic factors were identified as independent predictors of poorer OS and CSS, including age, advanced T stage, non-squamous histology, lower lobe primary site, positive resected lymph nodes, and pneumonectomy. IPTW analysis also did not reveal any significant survival benefit with CRT compared to CT.<br /><br />Although there was a slightly higher median OS and CSS in the CRT group compared to the CT group, these differences were not statistically significant. The study included a total of 1175 patients, of which 68.0% received neoadjuvant CRT and 32.0% received neoadjuvant CT.<br /><br />In conclusion, these findings suggest that the addition of radiotherapy to chemotherapy in the neoadjuvant treatment of stage III-N2 NSCLC patients does not provide significant survival benefits. It is important to consider various prognostic factors when determining the optimal treatment option and sequence for these patients. Further research is needed to explore other treatment strategies in this population.

Asset Subtitle

Marah Akhdar

Meta Tag

Speaker Marah Akhdar

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

chemoradiotherapy

chemotherapy

neoadjuvant treatment

stage III-N2

non-small cell lung cancer

NSCLC

overall survival

cancer-specific survival

SEER database

prognostic factors